Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres.

IF 4.8 2区医学 Q1 CLINICAL NEUROLOGY

Multiple Sclerosis Journal Pub Date : 2024-10-01 Epub Date: 2024-06-14 DOI:10.1177/13524585241260977

Gloria Dalla Costa, Letizia Leocani, Marco Pisa, Tommaso Croese, Vittorio Martinelli, Lucia Moiola, Francesca Sangalli, Bruno Colombo, Aiden Haghikia, Ralf Gold, Roberto Furlan, Giancarlo Comi

{"title":"Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres.","authors":"Gloria Dalla Costa, Letizia Leocani, Marco Pisa, Tommaso Croese, Vittorio Martinelli, Lucia Moiola, Francesca Sangalli, Bruno Colombo, Aiden Haghikia, Ralf Gold, Roberto Furlan, Giancarlo Comi","doi":"10.1177/13524585241260977","DOIUrl":null,"url":null,"abstract":"Background: While John Cunningham virus (JCV) is known to cause neuronal damage in progressive multifocal leukoencephalopathy (PML) among natalizumab-treated MS patients, its association with axonal loss in non-PML conditions remains unclear.Methods: In a cohort of 128 natalizumab-treated MS patients, serum neurofilament (sNfL) levels and JCV antibody titres were measured.Results: Among 128 patients (mean age = 38.4 years, 71.9% female), 51 (40%) were JCV positive. NfL levels increased by 15.3% for JCV index <0.7 (95% confidence interval [CI] = 0.963-1.381), by 18.6% for index 0.7-1.5 (95% CI = 1.009-1.394) and by 21.1% for index >1.5 (95% CI = 1.040-1.409) compared to JCV negative patients.Conclusion: These findings indicate a potential link between JCV burden and neuroaxonal degeneration in natalizumab-treated MS patients.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1561-1565"},"PeriodicalIF":4.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585241260977","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: While John Cunningham virus (JCV) is known to cause neuronal damage in progressive multifocal leukoencephalopathy (PML) among natalizumab-treated MS patients, its association with axonal loss in non-PML conditions remains unclear.

Methods: In a cohort of 128 natalizumab-treated MS patients, serum neurofilament (sNfL) levels and JCV antibody titres were measured.

Results: Among 128 patients (mean age = 38.4 years, 71.9% female), 51 (40%) were JCV positive. NfL levels increased by 15.3% for JCV index <0.7 (95% confidence interval [CI] = 0.963-1.381), by 18.6% for index 0.7-1.5 (95% CI = 1.009-1.394) and by 21.1% for index >1.5 (95% CI = 1.040-1.409) compared to JCV negative patients.

Conclusion: These findings indicate a potential link between JCV burden and neuroaxonal degeneration in natalizumab-treated MS patients.

查看原文本刊更多论文

纳他珠单抗治疗多发性硬化症患者的神经轴损害：JCV抗体滴度的作用。

背景：已知约翰-坎宁安病毒（JCV）会在纳他珠单抗治疗的多发性硬化症患者的进行性多灶性白质脑病（PML）中导致神经元损伤，但它与非PML情况下的轴突丢失的关系仍不清楚：在128名纳他珠单抗治疗的多发性硬化症患者中，测量了血清神经丝蛋白（sNfL）水平和JCV抗体滴度：结果：在 128 名患者（平均年龄为 38.4 岁，71.9% 为女性）中，有 51 人（40%）JCV 阳性。与 JCV 阴性患者相比，JCV 指数为 1.5 的 NfL 水平增加了 15.3% (95% CI = 1.040-1.409)：这些研究结果表明，在纳他珠单抗治疗的多发性硬化症患者中，JCV负担与神经轴变性之间存在潜在联系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Multiple Sclerosis Journal 医学-临床神经学

CiteScore

10.90

自引率

6.90%

发文量

186

审稿时长

3-8 weeks

期刊介绍： Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system. The journal for your research in the following areas: * __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics * __Epidemology and genetics:__ genetics epigenetics, epidemiology * __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures * __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management Print ISSN: 1352-4585